New treatment for depression

Boom in psychedelic therapies?Uploaded 23-08-22https://www.telegraph.co.uk/news/2022/08/20/magic-mushrooms-set-become-uks-ultimate-weapon-against-depression/https://www.theguardian.com/science/2022/apr/12/psilocybin-depression-brain-break-out-of-a-rut-magic-mushroomsShort-acting drugs, psychedelic experience, two-hour therapy session.Resetting brain networksHelping to end ingrained negative patterns of thought, and making patients far more receptive to therapy.Small Pharmahttps://smallpharma.comLeading the world’s first regulated clinical trial,DMT (dimethyltryptamine) with psychotherapy for major depressive disorder.Phase one done on healthy volunteersNext few months, reports from 42 patientsDr Carol Routledge, chief medical and scientific officerWe think that this treatment will really get to the root cause, rather than just dampening symptomsAlmost immediate benefitsBased on initial data that we already have, and other companies have, there’s going to be a fairly immediate impactIn terms of the psychedelic experience, we’re talking about 20 minutes, and then the integration therapy afterwards,we expect the antidepressant activity to be extremely durable … to last maybe three, four or five monthsImaging dataPsychedelics work on the brain networksMaking neural connections more flexible to brain plasticityYou can reset those networks in the brain, and then that leaves the brain much more receptive to therapy, which is why we bring it in straight afterwardsMedicines and Healthcare products Regulatory Agency (MHRA)Innovative Licensing and Access Pathway (ILAP)Brings organisations togetherSpeed up the time getting meds to patientsOther companies testing MDMA3,4-MethylenedioxymethamphetamineTherapy for post-traumatic stress disorder (PTSD)Psilocybin, (Clerkenwell Health)DepressionSmokingTerminal illnessPsychedelic experienceOut-of-body sensationsVisual or aural hallucinationsPsilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controlshttps://www.nature.com/articles/s41598-022-14512-3#Tab2University of British Columbia, Vancouver, July, 2022Psilocybin microdosingRepeated self-administration of mushrooms containing psilocybin,at doses small enough to not impact regular functioning. 3–5 times per week, of 0.1 to 0.3 g of dried mushroomsNaturalistic, observational designStudy approved, University of British Columbia Research Ethics Board (H19-03051)Psilocybin microdosers (n = 953)Non-m